Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

SEC Form 8-K: Press Release dated May 23 & May 24, 2024

BPTH_20240530_8-K

SEC Form 8-K: Press Release May 15, 2024

BPTH-Form_8-K_Q1-2024_Earnings_Release

SEC Form 10-Q for Period ending March 31, 2024

BPTH-Form_10-Q_Q1_2024

SEC Form S-1 dated April 24, 2024

BPTH_S-1_20240424

SEC Form 8-K: Other Events

BPTH_20240419_8-K-2

Prospectus Supplement (To Prospectus dated June 14, 2022) 424B5 S-3

BPTH_20240419_424B5_Preliminary-Prospectus_S-3

SEC Form 8-K: Entry Into a Material Definitive Agreement.

BPTH_8-K_20240419

Prospectus Supplement (To Prospectus dated June 14, 2022)

BPTH_424b5_2024-04-18

SEC Form 8-K: Press Release dated April 18. 2024

BPTH_Form_8-K_PR_20240418

SEC Form 8-K: Press Release dated April 15, 2024

BPTH_Form_8-K_PR_20240415

Bio-Path Holdings

All Rights Reserved

Office:

625 Stanwix Street
Pittsburgh, PA, 15222

T: (630) 708-0750

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us